Samsung Biologics Signs 241 Billion KRW Contract for Contract Manufacturing with Pfizer

by Lee Myeonghwan

Published 02 Mar.2023 14:45(KST)

Samsung Biologics announced on the 2nd that it has signed a contract worth 241 billion KRW with Pfizer for contract manufacturing organization (CMO) services.

Samsung Biologics Plant 3 Exterior View [Photo by Samsung Biologics]

The contract amount corresponds to 15.37% of Samsung Biologics' consolidated sales in 2021.

Hot Picks Today

"It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]

"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
"Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
"Am I Really in the Top 30%?" and "Worried About My Girlfriend in the Bottom 70%"... Buzz Over High Oil Price Relief Fund
"Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?

The contract period is from February 20, 2023, to December 31, 2029. A Samsung Biologics representative explained, "The contract end date may change depending on production schedules and other contract condition modifications."

한글 기사 보기

This content was produced with the assistance of AI translation services.